BDNF and myeloid sarcoma: Following demyelinating insult, they observed an increase in myelin sheet thickness, oligodendrocyte differentiation, and higher prevalence of myelinated axons, which shows the great potential of targeting pathways associated with BDNF in MS therapy [82].